Literature DB >> 9863852

Tuberculin skin test screening practices among US colleges and universities.

K A Hennessey1, J M Schulte, L Cook, M Collins, I M Onorato, S E Valway.   

Abstract

CONTEXT: Concern about transmission of Mycobacterium tuberculosis on college campuses has prompted some schools to institute tuberculin skin test screening of students, but this screening has never been evaluated.
OBJECTIVE: To describe tuberculin skin test screening practices and results of screening in colleges and universities in the United States. DESIGN AND
SETTING: Self-administered mail and telephone questionnaire in November and December 1995 to a stratified random sample of US 2-year and 4-year colleges and universities. MAIN OUTCOME MEASURES: Type of tuberculin screening required; types of schools requiring screening; number and rate of students with positive skin test results and/or diagnosed as having tuberculosis.
RESULTS: Of the 3148 US colleges and universities, 624 (78%) of 796 schools surveyed responded. Overall, 378 schools (61%) required tuberculin screening; it was required for all new students (US residents and international students) in 161 (26%) of 624 schools, all new international students but not new US residents in 53 (8%), and students in specific academic programs in 294 (47%). Required screening was more likely in 4-year vs 2-year schools, schools that belonged to the American College Health Association vs nonmember schools, schools with immunization requirements vs schools without, and schools with a student health clinic vs those without (P<.001 for all). Public and private schools were equally likely to require screening (64% vs 62%; P=.21). In the 378 schools with screening requirements, tine or multiple puncture tests were accepted in 95 (25%); test results were recorded in millimeters of induration in 95 (25%); and 100 (27%) reported collecting results in a centralized registry or database. Of the 168 (27%) of 624 schools accepting only Mantoux skin tests and reporting results for school years 1992-1993 through 1995-1996, 3.1% of the 348 368 students screened had positive skin test results (median percentage positive, 0.8%). International students had a significantly higher case rate for active tuberculosis than US residents (35.2 vs 1.1 per 100000 students screened).
CONCLUSIONS: Widespread tuberculin screening of students yielded a low prevalence of skin test reactors and few tuberculosis cases. To optimize the use of limited public health resources, tuberculin screening should target students at high risk for infection.

Entities:  

Mesh:

Year:  1998        PMID: 9863852     DOI: 10.1001/jama.280.23.2008

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  5 in total

1.  Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening.

Authors:  Akiko Kowada
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

2.  Health conditions among aging narcotics addicts: medical examination results.

Authors:  Yih-Ing Hser; Lillian Gelberg; Valerie Hoffman; Christine E Grella; William McCarthy; M Douglas Anglin
Journal:  J Behav Med       Date:  2004-12

3.  US college and university student health screening requirements for tuberculosis and vaccine-preventable diseases, 2012.

Authors:  Amy Jewett; Teal Bell; Nicole J Cohen; Kirsten Buckley; E Victor Leino; Susan Even; Suzanne Beavers; Clive Brown; Nina Marano
Journal:  J Am Coll Health       Date:  2016-01-05

4.  Estimating the impact of newly arrived foreign-born persons on tuberculosis in the United States.

Authors:  Yecai Liu; John A Painter; Drew L Posey; Kevin P Cain; Michelle S Weinberg; Susan A Maloney; Luis S Ortega; Martin S Cetron
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

5.  Private sector tuberculosis prevention in the US: Characteristics associated with interferon-gamma release assay or tuberculin skin testing.

Authors:  Erica L Stockbridge; Thaddeus L Miller; Erin K Carlson; Christine Ho
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.